Join our daily newsletter At The Bell to receive exclusive market insights
- Zelira Therapeutic’s (ZLD) share price is on the rise after releasing results of its study on its ZENIVOL drug as a therapeutic option to manage chronic insomnia symptoms
- In a white paper published by Zelira in collaboration with Emyria (EMD), the company detailed its analysis of longitudinal, real world data (RWD) generated from 94 patients diagnosed with chronic insomnia that was treated with ZENIVOL
- Key findings include the baseline reduction on the Insomnia Severity Index (ISI) from 19.5, known as moderate clinical insomnia to 14.3, known as subthreshold insomnia
- However, 27 per cent of severe clinical insomnia patients had no improvement in their ISI score
- Shares in Zelira are up 2.73 per cent, trading at $1.13 as of 1:44 pm AEST
Zelira Therapeutic’s (ZLD) share price rose after releasing results of its study on its ZENIVOL drug as a therapeutic option to manage chronic insomnia symptoms.
In a white paper published by Zelira in collaboration with Emyria (EMD), it gave a detailed analysis of longitudinal, real world data (RWD) generated from 94 patients diagnosed with chronic insomnia that was treated with ZENIVOL.
Key findings included the baseline reduction on the Insomnia Severity Index (ISI) from 19.5, known as moderate clinical insomnia to 14.3, known as subthreshold insomnia.
However, 27 per cent of severe clinical insomnia patients had no improvement in their ISI score.
For those patients with subthreshold insomnia at baseline, 20 per cent of them were able to reduce their ISI scores to no clinically significant insomnia with the remainder maintaining a subthreshold insomnia rating.
The company noted the primary indications of patients receiving ZENIVOL was chronic non-cancer pain, insomnia and post-traumatic stress disorder.
Further, a substantial proportion of active ZENIVOL patients were over the age of 65, suggesting that the drug is safe and effective in the cohort in the short to medium term.
Managing Director and CEO Dr Oludare Odumosu commented that the results are consistent with the previously published phase 1b/2a clinical trial.
“It continues to build the story for ZENIVOL as an effective and safe therapeutic treatment for chronic insomnia symptoms.
“These results build a strong platform to accelerate additional clinical and regulatory validations for our Rx products.”
Results published in the white paper is available on Zelira’s website.
Shares in Zelira were up 2.73 per cent, trading at $1.13 as of 1:44 pm AEST.
